Die Biotech- und Pharmabranche setzt ihre digitale Entwicklung mit hohem Tempo fort, während geopolitische und ökonomische Kräfte Probleme bereiten, die mithilfe einer die gesamte Lieferkette erfassenden und sorgfältig angepassten Strategie gelöst werden müssen. Erkunden Sie die aktuelle Vordenkerrolle von BCG im Bereich Biopharmaceuticals und gewinnen Sie wichtige Erkentnisse über die Zukunft der Life-Sciences-Branche.
A new consumer sentiment survey reveals concrete steps that health care providers can take to accelerate patients’ return.
What happens when longstanding channels of interaction no longer function? Companies are fundamentally changing the way they support the delivery of health care.
Preparing Localities for Action Against Novel Coronavirus (PLAN) is a scenario-planning tool that identifies potential US supply and demand imbalances down to the county level.
In their response to COVID-19, pharma and medtech companies have been true to their purpose. They now face questions that go beyond addressing the virus itself.
A new global survey reveals patient priorities around engagement, innovation and impact, and how pharma companies can benefit by becoming more patient centric.
BCG has taken a look at how biopharma can succeed in the next decade, and we’ve identified five major business imperatives.
Quantum computing has the potential to significantly accelerate, enhance the quality of, and reduce the costs of drug discovery.
An advanced algorithm helps doctors identify patients at risk of developing a serious kidney complication, enabling hospitals to lower treatment costs and save lives.
When biopharma companies apply data and analytics, they can make smarter commercial decisions, get better treatment information to physicians, and help save lives.
A recent analysis shows disturbing variations in the use of a key diagnostic for lung cancer patients. Adopting new protocols and tools can lead to better care.
COVID-19 and the New Leadership Agenda
The COVID-19 outbreak underscores the need to be resilient in the face of transformative global risk.
Launching an orphan treatment is more complicated than ever. Here’s how to successfully navigate the challenges.
Given the growing complexity of customers’ needs and other sales challenges, pharma companies should activate six sales force roles.
“Double down on your loyalists”—and other insights to improve sales team efficiency.
Winning the ’20s
How should leaders prepare their companies to thrive in the new decade?
Although women make up the majority of health care employees, men still dominate the corner office. Here are six ways to give women a fair shot at the top.
Pockets of opportunity await generic-drug companies that are prepared to adopt new strategies.
BCG’s 2019 benchmark study found that companies need to relentlessly manage the elements that demand the greatest spending—internal and contract manufacturing.
Even highly regulated and rigid industries can benefit from new ways of working.
Agile can help pharma companies deal with an intractable obstacle.
Bereits zum zehnten Mal analysiert der Biotech-Report der Boston Consulting Group (BCG) die wirtschaftliche Lage der medizinischen Biotechnologie in Deutschland. In seiner Jubiläumsausgabe blickt der Report auf die Eckdaten der biopharmazeutischen Industrie in Deutschland in den letzten zehn Jahren und leitet daraus einen Ausblick auf die nächste Dekade ab.
Machine learning can make it much easier to determine the probability of a startup’s success.
New technologies are transforming the pharmaceutical industry’s approach to R&D. What’s happening now in the field—and what’s coming next?
These new therapies are poised to revolutionize oncology. It all depends on reaching a larger patient base and simplifying manufacturing and the supply chain.
These curative treatments are often unique. They face a very different type of marketplace.
